SCHEMBL7182484

SCHEMBL7182484

CCCOc1ccc(PC(=O)c2c(C)cc(C)cc2C)c(OCCC)c1.[LiH]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37
SLC5A1 P13866 1/20 0.37
SLC5A2 P31639 1/20 0.37
ELANE P08246 1/20 0.36
THRB P10828 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
PLK1 P53350 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
RAB9A P51151 3/20 0.35
KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7182492 0.98 ITGB1 (0.40) ITGB1ITGA4MAPTALDH1A1GAA
SCHEMBL7181077 0.95 ITGB1 (0.45) ITGB1ITGA4ELANETHRBSMN1; SMN2
SCHEMBL7177461 0.93 ITGB1 (0.48) ITGB1ITGA4THRBTSHR
Lithium SCHEMBL7181087 0.93 ITGB1 (0.45) ITGB1ITGA4ELANETHRBSMN1; SMN2
SCHEMBL7180599 0.92 ITGB1 (0.47) ITGB1ITGA4THRBTSHR
SCHEMBL28012984 0.92 ITGB1 (0.49) ITGB1ITGA4THRBTSHR
Lithium SCHEMBL7177470 0.91 ITGB1 (0.48) ITGB1ITGA4THRBTSHR
SCHEMBL7179721 0.90 KMT2A (0.43) MAPTL3MBTL1LMNAKMT2ASLC5A1
SCHEMBL7189018 0.90 ITGB1 (0.42) ITGB1ITGA4MAPTALDH1A1GAA
SCHEMBL7188997 0.90 MAPT (0.38) MAPTALDH1A1GAAL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 ITGB1 2786/4885ITGA4 3521/4885MAPT 4870/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 ITGB1 3321/4885ITGA4 3643/4885MAPT 4859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.